A strength of this analysis is that the SPOTLIGHT and GLOW studies represent the largest sources to date for data on the global prevalence of CLDN18.2 positivity in patients with HER2-negative, LA unresectable or mG/GEJ adenocarcinoma. This evidence concerns the gene ERBB2 and gastroesophageal junction adenocarcinoma.